Anavex Life Sciences Corp (AVXL) - Total Assets
Based on the latest financial reports, Anavex Life Sciences Corp (AVXL) holds total assets worth $120.14 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anavex Life Sciences Corp - Total Assets Trend (2004–2025)
This chart illustrates how Anavex Life Sciences Corp's total assets have evolved over time, based on quarterly financial data. Also see Anavex Life Sciences Corp market cap and net worth for the company's overall valuation and market capitalisation.
Anavex Life Sciences Corp - Asset Composition Analysis
Current Asset Composition (September 2025)
Anavex Life Sciences Corp's total assets of $120.14 Million consist of 100.0% current assets and 0.0% non-current assets. Review debt load of Anavex Life Sciences Corp to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.8% |
| Accounts Receivable | $809.00K | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Anavex Life Sciences Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Anavex Life Sciences Corp share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anavex Life Sciences Corp's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2004.
- Cash Position: Cash and equivalents constituted 98.8% of total assets in 2025, down from 100.0% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Anavex Life Sciences Corp Competitors by Total Assets
Key competitors of Anavex Life Sciences Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
|
USA | $1.21 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $512.24 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Anavex Life Sciences Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.62 | 8.82 | 14.97 |
| Quick Ratio | 15.62 | 8.82 | 14.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $112.45 Million | $89.69 Million | $150.82 Million |
Anavex Life Sciences Corp - Advanced Valuation Insights
This section examines the relationship between Anavex Life Sciences Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 2.13 |
| Asset Growth Rate (YoY) | -23.4% |
| Total Assets | $103.81 Million |
| Market Capitalization | $220.62 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Anavex Life Sciences Corp's assets at a significant premium (2.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Anavex Life Sciences Corp's assets decreased by 23.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Anavex Life Sciences Corp (2004–2025)
The table below shows the annual total assets of Anavex Life Sciences Corp from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $103.81 Million | -23.42% |
| 2024-09-30 | $135.57 Million | -12.19% |
| 2023-09-30 | $154.39 Million | +1.10% |
| 2022-09-30 | $152.70 Million | -5.51% |
| 2021-09-30 | $161.62 Million | +367.88% |
| 2020-09-30 | $34.54 Million | +36.37% |
| 2019-09-30 | $25.33 Million | +3.91% |
| 2018-09-30 | $24.38 Million | -12.44% |
| 2017-09-30 | $27.84 Million | +193.08% |
| 2016-09-30 | $9.50 Million | -38.60% |
| 2015-09-30 | $15.47 Million | +110.37% |
| 2014-09-30 | $7.35 Million | +1768.98% |
| 2013-09-30 | $393.45K | +2891.33% |
| 2012-09-30 | $13.15K | -93.52% |
| 2011-09-30 | $203.04K | -38.44% |
| 2010-09-30 | $329.85K | -19.28% |
| 2009-09-30 | $408.64K | +5560.66% |
| 2008-09-30 | $7.22K | +28776.00% |
| 2007-09-30 | $25.00 | -99.80% |
| 2006-09-30 | $12.49K | +1178.92% |
| 2005-09-30 | $977.00 | -96.52% |
| 2004-09-30 | $28.11K | -- |
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), h… Read more